Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Biphenotypic, Acute 3Burkitt Lymphoma 3Oropharyngeal Neoplasms 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hematologic Neoplasms 1Cranial Nerve Diseases 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 8fludarabine phosphate 7tagraxofusp 6venetoclax 5fludarabine 5Whole-Body Irradiation 4Mycophenolic Acid 4Methotrexate 4Thiotepa 3Dexamethasone 3Cytarabine 3Cyclosporine 3Calcium Dobesilate 3merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Vincristine 2Tacrolimus 2Specimen Handling 2Rituximab 2Peripheral Blood Stem Cell Transplantation 2Cyclosporins 2Azacitidine 2relmapirazin 1prednylidene 1lorvotuzumab mertansine 1exifone 1deltacortene 1azathiopurine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Blastic Plasmacytoid Dendritic Cell Neoplasm × exifone × Clear all
NCT04216524 2026-04-14

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡